Riskpilot← Back to searchSign inGet full accessREJUVI AS
ASActiveOrg 923886796Ensjøveien 21E, 0655 OsloOther human health activities n.e.c. · NACE 8699Est. 20193 employees
Revenue 2024
NOK 1,2M
-19% vs 2023
EBITDA margin
-36.8%
+24% vs 2023
Equity ratio
-1087.3%
Financial strength
Net profit 2024
NOK -434K
+24% vs 2023
| Revenue | NOK 1,2M | -19% |
| EBITDA | NOK -431K | +24% |
| Net profit | NOK -434K | +24% |
| Total assets | NOK 227K | +109% |
| Equity | NOK -2,5M | -21% |
| Employees | 3 | — |
Legal name
REJUVI AS
Org number
923886796
Legal form
Aksjeselskap
NACE code
8699 · Other human health activities n.e.c.
Founded
25. november 2019
Share capital
NOK 30 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder eller nestleder hver for seg. Daglig leder eller styrets leder hver for seg.
Company purpose
Kosmetisk sykepleie og hudbehandlinger. Hudforyngelse med injeksjoner, ipl og laserbehandlinger. Prp behandlinger, diamantslip, kjemiske peelinger og behandlinger ved termokoagulering. Plasma/ fibroblastbehandlinger.
Address
Ensjøveien 21E, 0655 Oslo
Phone
+4748454870
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 230 | 552 | 662 | 1 450 | 1 171 |
| Staff expenses | −0 | −0 | −0 | −922 | −785 |
| EBITDA | −1 065 | −661 | −853 | −567 | −431 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −1 065 | −661 | −853 | −567 | −431 |
| Net financials | −0 | −2 | −5 | −2 | −2 |
| Profit before tax | −1 065 | −663 | −859 | −570 | −434 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −1 065 | −660 | −859 | −570 | −434 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 162 | 303 | 122 | 109 | 227 |
| Equity | −115 | −609 | −1 468 | −2 037 | −2 471 |
| Long-term debt | 172 | 838 | 1 438 | 1 925 | 2 518 |
| Short-term debt | 105 | 74 | 151 | 221 | 180 |
| Total debt | 277 | 913 | 1 589 | 2 146 | 2 698 |
EBITDA margin
-36.8%
This company
15.8%
Market median
-333% vs market
20202024
Equity ratio
-1087.3%
This company
38.2%
Market median
-2946% vs market
20202024
Return on equity
-43364800.0%
This company
18.4%
Market median
-235678361% vs market
20202024
Net profit margin
-37.0%
This company
8.1%
Market median
-557% vs market
20202024
Asset turnover
5.15×
This company
1.12×
Market median
+360% vs market
20202024
Debt / equity
1.09×
This company
0.62×
Market median
-76% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SH Chief Executive Officer | Chief Executive Officer | 2019 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Chairman | 2019 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Js Clinique As
REJUVI AS Board members of REJUVI AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Stephen Harrison Smith | Chief Executive Officer | 0 companies |
| Jill-Anett Smith | Deputy Chairman | 0 companies |